Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.31 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21475343 | 1.00 | PRKCA (0.31) | PRKCACYP1A2HSD17B3SMN1; SMN2 | |
| SCHEMBL21475287 | 1.00 | PRKCA (0.31) | PRKCACYP1A2HSD17B3SMN1; SMN2 | |
| SCHEMBL21479501 | 0.96 | CYP1A2 (0.33) | CYP1A2HSD17B3 | |
| SCHEMBL21479529 | 0.95 | CYP1A2 (0.35) | PRKCACYP1A2HSD17B3 | |
| SCHEMBL21479527 | 0.95 | CYP1A2 (0.35) | PRKCACYP1A2HSD17B3 | |
| SCHEMBL21479549 | 0.95 | CYP1A2 (0.35) | PRKCACYP1A2HSD17B3 | |
| SCHEMBL21475318 | 0.93 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL21475295 | 0.87 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL21475409 | 0.86 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL23007849 | 0.82 | ICAM1 (0.38) | PRKCACYP1A2HSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210047283-A1 | NOVEL LACTONE COMPOUND AND NOVEL ETHER COMPOUND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047283-A1 | NOVEL LACTONE COMPOUND AND NOVEL ETHER COMPOUND | NR0B1, CBR1, DCXR | PRKCA 3689/4885CYP1A2 155/4885HSD17B3 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.